Protalix BioTherapeutics Inc.
PLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$212.71M
Close$
$-2.48
189.5% downside
Current Fair Value
189.5% downsideOvervalued by 189.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $212.71 Million |
|---|---|
| Enterprise Value | $194.50 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | 0.01 |
| Outstanding Shares | 79,986,325 |
Return
| Return on Equity | 26.53% |
|---|---|
| Return on Assets | 17.17% |
| Return on Invested Capital | 24.25% |
Valuation & Multiples
| P/E Ratio | 10.95 |
|---|---|
| PEG | 0.5 |
| Price to Sales | 2.77 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.41 |
| Enterprise Value to EBIT | 10.16 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$0.27
Average shareholder expectationRevenue Estimate
$37.80 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$12.41 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6529▲ 13.43% |
|---|---|
| Total Calls | 235,400▼ 9.64% |
| Total Puts | 153,700▲ 13.77% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 18.32%▼ 2.80% |
|---|---|
| Total Invested | $34.13M▼ 6.67% |
| Investors Holding | 109▲ 3.00% |
ESG Score
No data
About Protalix BioTherapeutics Inc.
CEO: Dror Bashan